Akademska digitalna zbirka SLovenije - logo
E-viri
Recenzirano Odprti dostop
  • Multigene Panel Germline Te...
    Lhotova, Klara; Stolarova, Lenka; Zemankova, Petra; Vocka, Michal; Janatova, Marketa; Borecka, Marianna; Cerna, Marta; Jelinkova, Sandra; Kral, Jan; Volkova, Zuzana; Urbanova, Marketa; Kleiblova, Petra; Machackova, Eva; Foretova, Lenka; Hazova, Jana; Vasickova, Petra; Lhota, Filip; Koudova, Monika; Cerna, Leona; Tavandzis, Spiros; Indrakova, Jana; Hruskova, Lucie; Kosarova, Marcela; Vrtel, Radek; Stranecky, Viktor; Kmoch, Stanislav; Zikan, Michal; Macurek, Libor; Kleibl, Zdenek; Soukupova, Jana

    Cancers, 04/2020, Letnik: 12, Številka: 4
    Journal Article

    Ovarian cancer (OC) is the deadliest gynecologic malignancy with a substantial proportion of hereditary cases and a frequent association with breast cancer (BC). Genetic testing facilitates treatment and preventive strategies reducing OC mortality in mutation carriers. However, the prevalence of germline mutations varies among populations and many rarely mutated OC predisposition genes remain to be identified. We aimed to analyze 219 genes in 1333 Czech OC patients and 2278 population-matched controls using next-generation sequencing. We revealed germline mutations in 18 OC/BC predisposition genes in 32.0% of patients and in 2.5% of controls. Mutations in , , , and mismatch repair genes conferred high OC risk (OR > 5). Mutations in and were associated with moderate risk (both OR = 3.5). mutations dominated in almost all clinicopathological subgroups including sporadic borderline tumors of ovary (BTO). Analysis of remaining 201 genes revealed somatic mosaics in and germline mutations in and associating with a high/moderate OC risk significantly; however, further studies are warranted to delineate their contribution to OC development in other populations. Our findings demonstrate the high proportion of patients with hereditary OC in Slavic population justifying genetic testing in all patients with OC, including BTO.